|
clinical trial phase 2/3
|
CTO_0000031 |
|
|
clinical trial phase
|
CTO_0000201 |
|
|
phase 2 vaccine trial
|
VO_0000428 |
|
|
Brazilian clinical trial registry identifier
|
CTO_0000030 |
|
|
phase 4 vaccine trial
|
VO_0000430 |
|
|
age_between_18_and_64
|
CTO_0000026 |
|
|
Age
|
NCIT_C25150 |
|
|
human subject enrollment
|
OBI_0600004 |
|
|
selection
|
OBI_0001928 |
|
|
JMACCT clinical trials registry
|
CTO_0000025 |
|
|
Study Type
|
NCIT_C142175 |
|
|
planned process
|
OBI_0000011 |
|
|
German clinical trials register
|
CTO_0000024 |
|
|
Lebanese clinical trials registry
|
CTO_0000023 |
|
|
case-control study design
|
OBI_0002624 |
|
|
study design
|
OBI_0500000 |
|
|
number of participants
|
CTO_0000028 |
|
|
investigation agent role
|
OBI_0000202 |
|
|
study status
|
OPMI_0000327 |
|
|
status
|
OPMI_0000326 |
|
